areta offers to its customers a GMP facility, authorized by AIFA, to produce and release biopharmaceuticals for clinical trials. In 2004, areta have been authorized to produce cells for cell therapy and in 2009 the authorization was extended to become truly multipurpose, enabling the company to manufacture different types of biodrugs (cells, proteins, immunological products, plasmids for DNA-based vaccines), as well as execute aseptic filling, final lyophilization and release of finished product.
The expertise of GMP's staff is founded on a consolidated experience in the field of research and development of innovative pharmaceuticals, and on constant training as required by the internal Quality System. This particular feature makes areta a dynamic partner for the development of new molecules, from process development to support of clinical trials.
The facility and the acquired know-how allow areta to simultaneously manage projects which are very different one from the other, both in terms of product categories and quantity of the finished product. The processes provided are linear, flexible, highly personalized and easily scalable, according to the customer needs.